(CLPT) Clearpoint Neuro - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 343m USD | Total Return: -5.7% in 12m
Avg Turnover: 5.00M
Qual. Beats: -2
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -9.8 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -10.72 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
ClearPoint Neuro, Inc. (CLPT) is a medical device firm specializing in platforms for minimally invasive neurosurgical procedures. The company’s core product suite includes the ClearPoint system, which integrates hardware, trajectory-guiding disposables, and navigation software to assist physicians in surgical planning and real-time monitoring. Its portfolio also features the Prism Neuro laser therapy system for tissue coagulation and the IRRAflow fluid exchange platform.
Operating within the high-barrier Health Care Equipment sector, the company utilizes a razor-and-blade business model where the placement of hardware systems facilitates recurring revenue through specialized disposable cannulas and software licenses. Beyond surgical hardware, ClearPoint provides clinical and regulatory consulting services to pharmaceutical partners, supporting the transition of neurologic therapies from preclinical stages to human trials.
Strategic growth is supported by collaboration agreements with established entities such as Philips and UCB Biopharma to integrate neuro-navigation technology into broader clinical workflows. Investors interested in deeper valuation metrics should examine the companys profile on ValueRay. ClearPoint Neuro is headquartered in Solana Beach, California, and transitioned from its former identity as MRI Interventions in 2020.
- Expansion of biologics and drug delivery partnerships increases high-margin service revenue
- FDA clearance of clinical-stage neuro-navigation software drives hospital system adoption rates
- Growth in disposable SmartFlow cannula volume improves recurring revenue and gross margins
- Strategic partnerships with pharmaceutical firms accelerate pipeline for gene therapy delivery systems
- High research and development spending delays path to sustained GAAP profitability
| Net Income: -29.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA 10.46 > 1.0 |
| NWC/Revenue: 111.8% < 20% (prev 53.82%; Δ 57.96% < -1%) |
| CFO/TA -0.28 > 3% & CFO -25.7m > Net Income -29.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.5m) vs 12m ago 6.59% < -2% |
| Gross Margin: 61.82% > 18% (prev 0.61%; Δ 6.12k% > 0.5%) |
| Asset Turnover: 65.78% > 50% (prev 107.2%; Δ -41.42% > 0%) |
| Interest Coverage Ratio: -9.82 > 6 (EBITDA TTM -23.9m / Interest Expense TTM 2.71m) |
| A: 0.49 (Total Current Assets 54.9m - Total Current Liabilities 9.48m) / Total Assets 93.4m |
| B: -2.42 (Retained Earnings -226.5m / Total Assets 93.4m) |
| C: -0.43 (EBIT TTM -26.6m / Avg Total Assets 61.7m) |
| D: -2.96 (Book Value of Equity -220.6m / Total Liabilities 74.6m) |
| Altman-Z'' = -10.72 = D |
| DSRI: 1.88 (Receivables 8.66m/3.65m, Revenue 40.6m/32.2m) |
| GMI: 0.99 (GM 61.82% / 61.20%) |
| AQI: 10.17 (AQ_t 0.24 / AQ_t-1 0.02) |
| SGI: 1.26 (Revenue 40.6m / 32.2m) |
| TATA: -0.04 (NI -29.1m - CFO -25.7m) / TA 93.4m) |
| Beneish M = 3.28 (Cap -4..+1) = D |
As of May 27, 2026, the stock is trading at USD 11.82 with a total of 506,425 shares traded.
Over the past week, the price has changed by +6.20%,
over one month by +5.44%,
over three months by -18.09% and
over the past year by -5.74%.
Clearpoint Neuro has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CLPT.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22 | 86.1% |
P/E Forward = 12.1065
P/S = 8.4473
P/B = 18.2093
P/EG = 0.605
Revenue TTM = 40.6m USD
EBIT TTM = -26.6m USD
EBITDA TTM = -23.9m USD
Long Term Debt = 49.6m USD (from longTermDebt, last quarter)
Short Term Debt = 234k USD (from shortTermDebt, last quarter)
Debt = 77.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.9m
Net Debt = 41.9m USD (calculated: Debt 77.5m - CCE 35.6m)
Enterprise Value = 385.0m USD (343.1m + Debt 77.5m - CCE 35.6m)
Interest Coverage Ratio = -9.82 (Ebit TTM -26.6m / Interest Expense TTM 2.71m)
EV/FCF = -14.42x (Enterprise Value 385.0m / FCF TTM -26.7m)
FCF Yield = -6.94% (FCF TTM -26.7m / Enterprise Value 385.0m)
FCF Margin = -65.75% (FCF TTM -26.7m / Revenue TTM 40.6m)
Net Margin = -71.57% (Net Income TTM -29.1m / Revenue TTM 40.6m)
Gross Margin = 61.82% ((Revenue TTM 40.6m - Cost of Revenue TTM 15.5m) / Revenue TTM)
Gross Margin QoQ = 62.24% (prev 61.52%)
Tobins Q-Ratio = 4.12 (Enterprise Value 385.0m / Total Assets 93.4m)
Interest Expense / Debt = 3.49% (Interest Expense 2.71m / Debt 77.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -21.0m (EBIT -26.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.79 (Total Current Assets 54.9m / Total Current Liabilities 9.48m)
Debt / Equity = 4.12 (Debt 77.5m / totalStockholderEquity, last quarter 18.8m)
Debt / EBITDA = -1.75 (negative EBITDA) (Net Debt 41.9m / EBITDA -23.9m)
Debt / FCF = -1.57 (negative FCF - burning cash) (Net Debt 41.9m / FCF TTM -26.7m)
Total Stockholder Equity = 20.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.08% (Net Income -29.1m / Total Assets 93.4m)
RoE = -11.76% (Net Income TTM -29.1m / Total Stockholder Equity 247.1m)
RoCE = -8.96% (EBIT -26.6m / Capital Employed (Equity 247.1m + L.T.Debt 49.6m))
RoIC = -24.96% (negative operating profit) (NOPAT -21.0m / Invested Capital 84.2m)
WACC = 13.66% (E(343.1m)/V(420.6m) * Re(16.12%) + D(77.5m)/V(420.6m) * Rd(3.49%) * (1-Tc(0.21)))
Discount Rate = 16.12% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 86.67 | Cagr: 8.43%
[DCF] Fair Price = unknown (Cash Flow -26.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.15 | # QB: -2
Revenue Correlation: 98.90 | Revenue CAGR: 24.47% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.29 | Chg30d=-12.43% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=-9.71% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.11 | Chg30d=-14.77% | Revisions=-33% | GrowthEPS=-23.7% | GrowthRev=+43.7%
EPS next Year (2027-12-31): EPS=-0.94 | Chg30d=-15.34% | Revisions=+0% | GrowthEPS=+15.6% | GrowthRev=+20.4%
[Analyst] Revisions Ratio: -33%